Superior Group of Companies Reports Second Quarter 2026 Results

Adjusted earnings more than doubled, but headline net income fell on a $2.6M impairment.

Risk flags

• ●The $2.6 million tradename impairment charge in the Healthcare Apparel segment signals potential brand or segment underperformance, which could indicate ongoing challenges not fully captured in adjusted metrics.
• ●Reported net income declined year-over-year despite higher sales and improved adjusted earnings, highlighting the risk that one-off charges or operational issues could continue to impact GAAP profitability.
• ●The absence of segment-level revenue and margin breakdowns limits transparency into the sources of growth and risk, making it harder for investors to assess the durability of recent improvements.

Bottom line

Superior Group of Companies delivered modest sales growth and strong adjusted earnings in Q2 2026, but headline net income fell due to a $2.6 million impairment in Healthcare Apparel. The company’s guidance for the full year is for incremental improvement, not a step change, and all projections are near-term. Dividend continuity signals stability, but lack of segment detail and the impairment charge raise questions about the sustainability of performance. The narrative is credible at the headline and adjusted levels, but deeper insight into segment trends and recurring vs. non-recurring items would be needed for a stronger investment case. The most important takeaway: underlying adjusted profitability is improving, but headline results are vulnerable to one-off charges.

Announcement summary

(NASDAQ: SGC) Superior Group of Companies, Inc. announced second quarter 2026 net sales of $147.8 million, up from $144.0 million in the prior year second quarter. Net income for the quarter was $1.2 million, including a non-cash tradename impairment charge of $2.6 million ($2.0 million after tax), compared to $1.6 million in the prior year second quarter. Adjusted EBITDA was $7.7 million, up from $6.1 million in the prior year second quarter, and adjusted net income was $3.2 million or $0.21 per diluted share, more than double the prior year's $0.10 per diluted share. The Board of Directors declared a quarterly dividend of $0.14 per share, payable August 28, 2026 to shareholders of record as of August 14, 2026. The company continues to forecast full-year 2026 net sales in the range of $572.0 million to $585.0 million, up from 2025 net sales of $566.2 million, and full-year adjusted earnings per diluted share in the range of $0.54 to $0.66, up from $0.46 in 2025. As of June 30, 2026, cash and cash equivalents were $22,787,000, and total assets were $408,520,000. The company recorded a tradename impairment charge in the Healthcare Apparel segment of $2.6 million during the quarter.

Disagree with this article?